On Tuesday morning in San Diego, Dexcom — a provider of continuous glucose monitoring (CGM) solutions for patients with diabetes — announced that the U.S. Food and Drug Administration (FDA) has approved the Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System.
With wireless Bluetooth technology built into the device transmitter, the G5 Mobile CGM System “is the first and only fully mobile CGM system approved by the FDA for both adults and children as young as 2 years of age that sends glucose data directly to a smartphone.”
This technology, in short, frees users from the need to carry a separate receiver.
The new transmitter securely sends vital glucose information directly to an app on iOS-enabled devices for real-time diabetes management. Android applications will follow early next year.
“Dexcom is rapidly advancing technology for continuous glucose monitoring devices to improve diabetes management. Since January, the company has introduced the G4 PLATINUM CGM with Share, apps to enable the first CGM on the Apple WatchTM and now the Dexcom G5 Mobile CGM. These advances are making diabetes management more convenient and flexible than ever before,” says Kevin Sayer, President and Chief Executive Officer of Dexcom. “We are excited for the promise this new technology holds for patients and caregivers.”